Loading financial data...

Rani Therapeutics Holdings, Inc. (RANI) Financial Statements | Global Financial Data

Rani Therapeutics Holdings, Inc.

RANISEC EDGAR

Pharmaceutical Preparations(CA)CIK: 1856725

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	—	$2.7M	$462.0K
Research and Development Expense	$39.6M	$36.6M	$26.5M	$12.0M
Operating Expenses	$66.1M	$63.5M	$54.3M	-$17.0M
Operating Income (Loss)	-$66.1M	-$63.5M	-$51.6M	-$16.5M
Interest Expense	$5.1M	$1.1M	$466.0K	$124.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	-$63.3M	-$53.0M	-$16.7M
Income Tax Expense (Benefit)	$0.00	$70.0K	$41.0K	$35.0K
Net Income (Loss) Attributable to Parent	-$34.0M	-$30.6M	-$8.3M	-$8.3M
Earnings Per Share, Basic

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$57.9M	$108.0M	$124.2M	$79.4M
Assets, Current	$50.8M	$100.9M	$119.6M	$74.9M
Cash and Cash Equivalents, at Carrying Value	$5.9M	$27.0M	$117.5M	$73.1M
Liabilities	$32.5M	$34.0M	$2.6M	$8.0M
Liabilities, Current	$8.0M	$4.8M	$2.6M	$5.3M
Long-term Debt	$25.0M	$30.0M	$30.0M	—
Accounts Payable, Current	$648.0K	$1.5M	$1.1M	$537.0K
Stockholders' Equity Attributable to Parent	$12.9M	$36.9M	$47.4M	-$113.3M
Weighted Average Number of Shares Outstanding, Basic

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$51.2M	-$46.5M	-$32.2M	-$15.0M
Net Cash Provided by (Used in) Investing Activities	$29.9M	-$72.4M	-$506.0K	-$1.2M
Net Cash Provided by (Used in) Financing Activities	$233.0K	$29.0M	$77.1M	$72.7M
Payments to Acquire Property, Plant, and Equipment	$1.2M	$1.6M	$506.0K	$1.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)